Further, combined induction of ferroptosis and immune checkpoint inhibitors (ICIs) indicated synergistic anti-tumor activity, providing significant avenues for future research might and potentially driving immunotherapy of cancer to promising results, especially on PD-1 and CTLA-4 targets [40, 42]. The gene discussed is CTLA4; the disease is cancer.